The Christie Foundation Trust Annual Report and Accounts 2021-22

The Christie NHS Foundation Trust Annual Report & Accounts 2021-22

the bloodstream with the goal of matching a targeted treatment. Grants and Infrastructure Funding to expand our reach New funding awards totalling £2.5million were obtained for the PROTIS trial from Cancer Research UK and the TOURIST trial from National Institute for Health Research-Health Technology Assessment (NIHR-HTA). PROTIS, led by Dr David Thomson will evaluate proton beam radiotherapy for treatment of sinonasal (head and neck) cancer. TOURIST, led by Dr David Woolf and designed in collaboration with the National Cancer Research Institute (NCRI) Lung research group will define the impact of radiotherapy treatment in 1000 patients nationally with advanced, metastatic lung cancer. Funding was renewed for The NIHR Manchester Clinical Research Facility in which The Christie is a key partner and The CRUK Manchester Centre to further expand research activity. Publications of our Research In 2021 we led or contributed to ~ 400 peer reviewed publications. Selected publications of real-world evidence / observational outcomes research (First author, journal): • Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID 19 reveals features associated with outcome (Dr Rebecca Lee, ESMO Open). • Emergency Presentations of Immune Checkpoint Inhibitor-Related Endocrinopathies (Dr Tim Cooksley, The Journal of Emergency Medicine) • Enrolment of older adults with cancer in early phase trials (Dr Fabio Gomes, Age and Ageing) • A novel model and infrastructure for clinical outcomes data collection and their systematic evaluation for UK patients receiving proton beam therapy (Dr Ed Smith, Clinical Oncology)

• Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33 year experience in 14,311 women (Prof Gareth Evans, Breast Cancer Research and Treatment) • Long term outcomes for patients with peritoneal acellular mucinosis secondary to low grade appendiceal mucinous neoplasms (T Evans European Journal of Surgical Oncology • Evaluation of safety and effectiveness of prostate-specific antigen (PSA) monitoring in primary care after discharge from hospital based follow-up following prostate cancer treatment European Journal of Cancer Care Selected publications of biobank research (First author, journal): • Early adaptation of colorectal cancer cells to the peritoneal cavity is associated with activation of stem-ness programs and local inflammation (Jorge Burriuso, Clinical Cancer Research) • Helen Adderley The utility of TP53 and PIK3CA mutations as prognostic biomarkers in salivary adenoid cystic carcinoma (Dr Helen Adderley, Oral Oncology) Selected publications of clinical trials (First author, journal): • Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials (Prof Ananya Choudhury, Lancet Oncology) • Objective Responses to first line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. (Robert Morgan, Lancet Oncology) • PROCLAIM-CX-072 FIH, dose finding - advanced solid tumours (Prof Fiona Thistlethwaite, Journal for Immunotherapy of Cancer)

25